Merck's (NYSE:MRK) third-quarter sales rose 5% to about $18.1 billion, but the company says about $550 million of the gain came from the timing of customer purchases. Shares rose about 5% in Thursday morning trading. Strip out that timing and sales barely grew. The encouraging part is that the Keytruda Qlex shot and Winrevair are now scaling fast enough to offset steep generic losses on older drugs. Key Numbers What It Means
CryptoAlerta — análise de criptomoedas e mercado em tempo real